Lung cancer

Immunotherapy with PD1/PD-L1checkpoint inhibition is approved for treatment of non-small cell lung cancer, however PD-L1 has been shown to have limited performance as companion diagnostics. There is thus a need for more sensitive and specific biomarkers, as well as additional personalized treatment strategies for improved survival. We use spatial omics to identify and characterize immune infiltration structures in non-small cell lung cancer. The cellular and molecular composition of different immune infiltration types are assessed in relation to survival, with the objective to identify spatial biomarker signatures for more precise patient stratification.

Page Manager: jana.hladilkova@immun.lth.se | 2021-08-19